Sarepta’s stock plunges after Duchenne gene therapy fails to meet main goal in key trial

The Cambridge biotech’s stock price was cut in half Tuesday morning after it announced late Monday that its gene therapy to treat Duchenne muscular dystrophy failed to meet the primary goal of a large Phase 3 trial. It plans to seek full approval regardless.